The present disclosure is generally directed to an anucleated cell-based platforms for encapsulation and delivery of agricultural compounds. Disclosed herein are compositions for the stable and targeted delivery of agricultural compounds within achromosomal and/or anucleated cells. The present disclosure also provides methods of improving encapsulation and retention of agricultural compounds in achromosomal and/or anucleated cells,

The present disclosure is generally directed to an anucleated cell-based platforms for encapsulation and delivery of agricultural compounds. Disclosed herein are compositions for the stable and targeted delivery of agricultural compounds within achromosomal and/or anucleated cells. The present disclosure also provides methods of improving encapsulation and retention of agricultural compounds in achromosomal and/or anucleated cells,

The present disclosure discloses a method for isolating and purifying Lactobacillus rhamnosus ZFM216 bacteriocin, the method including the following steps: preparing L. rhamnosus ZFM216 fermentation supernatant; treating the fermentation supernatant with macroporous adsorption resin method to obtain a crude protein extract; isolating the crude protein extract by gel chromatography to obtain a preliminary purified protein solution; and then performing purification by reversed-phase high performance liquid chromatography (HPLC) to obtain an L. rhamnosus ZFM216 bacteriocin solution. The present disclosure further provides use of the L. rhamnosus bacteriocin in anti-Staphylococcus aureus.

The present disclosure discloses a method for isolating and purifying Lactobacillus rhamnosus ZFM216 bacteriocin, the method including the following steps: preparing L. rhamnosus ZFM216 fermentation supernatant; treating the fermentation supernatant with macroporous adsorption resin method to obtain a crude protein extract; isolating the crude protein extract by gel chromatography to obtain a preliminary purified protein solution; and then performing purification by reversed-phase high performance liquid chromatography (HPLC) to obtain an L. rhamnosus ZFM216 bacteriocin solution. The present disclosure further provides use of the L. rhamnosus bacteriocin in anti-Staphylococcus aureus.

The present invention provides a novel protein and biologically-active fragments and variants thereof with advantageous therapeutic and cosmetic uses. Also provided are methods of using the proteins, as well as methods of producing the proteins using a recombinant cell. Further provided are recombinant host cells transformed with a polynucleotide sequence that encodes the expression of the proteins.

The present invention provides a novel protein and biologically-active fragments and variants thereof with advantageous therapeutic and cosmetic uses. Also provided are methods of using the proteins, as well as methods of producing the proteins using a recombinant cell. Further provided are recombinant host cells transformed with a polynucleotide sequence that encodes the expression of the proteins.

The present invention provides at least one protein selected from the group consisting of the following proteins (a) to (d): (a) a protein which is composed of an amino acid sequence set forth in SEQ ID NO: 1; (b) a protein which is, in the amino acid sequence set for the in SEQ ID NO: 1, composed of an amino acid sequence in which one or more amino acids other than serine, leucine, phenylalanine, serine, and aspartic acid at positions 334 to 338 are substituted, deleted, inserted, and/or added and has an effect of improving the immunostimulatory activity of exopolysaccharides of lactic acid bacteria; (c) a protein which is composed of an amino acid sequence having 80% or more identity with the amino acid sequence set forth in SEQ ID NO: 1, has serine, leucine, phenylalanine, serine, and aspartic acid from the N-terminal side as amino acids corresponding to positions 334 to 338 of the amino acid sequence set forth in SEQ ID NO: 1, and has an effect of improving the immunostimulatory activity of exopolysaccharides of lactic acid bacteria; and (d) a protein which is composed of an amino acid sequence encoded by a DNA that hybridizes under stringent conditions with a complementary strand of a DNA composed of the nucleotide sequence set forth in SEQ ID NO: 2, has serine, leucine, phenylalanine, serine, and aspartic acid from the N-terminal side as amino acids corresponding to positions 334 to 338 of the amino acid sequence set forth in SEQ ID NO: 1, and has an effect of improving the immunostimulatory activity of exopolysaccharides of lactic acid bacteria.

The present invention provides at least one protein selected from the group consisting of the following proteins (a) to (d): (a) a protein which is composed of an amino acid sequence set forth in SEQ ID NO: 1; (b) a protein which is, in the amino acid sequence set for the in SEQ ID NO: 1, composed of an amino acid sequence in which one or more amino acids other than serine, leucine, phenylalanine, serine, and aspartic acid at positions 334 to 338 are substituted, deleted, inserted, and/or added and has an effect of improving the immunostimulatory activity of exopolysaccharides of lactic acid bacteria; (c) a protein which is composed of an amino acid sequence having 80% or more identity with the amino acid sequence set forth in SEQ ID NO: 1, has serine, leucine, phenylalanine, serine, and aspartic acid from the N-terminal side as amino acids corresponding to positions 334 to 338 of the amino acid sequence set forth in SEQ ID NO: 1, and has an effect of improving the immunostimulatory activity of exopolysaccharides of lactic acid bacteria; and (d) a protein which is composed of an amino acid sequence encoded by a DNA that hybridizes under stringent conditions with a complementary strand of a DNA composed of the nucleotide sequence set forth in SEQ ID NO: 2, has serine, leucine, phenylalanine, serine, and aspartic acid from the N-terminal side as amino acids corresponding to positions 334 to 338 of the amino acid sequence set forth in SEQ ID NO: 1, and has an effect of improving the immunostimulatory activity of exopolysaccharides of lactic acid bacteria.

The subject invention provides compositions and methods for inhibiting viral infections. Preferred embodiments of the invention provide pharmaceutical compositions, and the methods of using the same, comprising a strain of Lactobacillus fermentum bacterium, or bioactive extracts thereof.

The subject invention provides compositions and methods for inhibiting viral infections. Preferred embodiments of the invention provide pharmaceutical compositions, and the methods of using the same, comprising a strain of Lactobacillus fermentum bacterium, or bioactive extracts thereof.